Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Otto Metzger, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stamford Hospital
Stamford, Connecticut, United States
- Eastern Maine Medical Center
Brewer, Maine, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber at St. Elizabeth'S Medical Center
Boston, Massachusetts, United States
- Df/bwcc at Milford Regional Medical Center
Milford, Massachusetts, United States
- Df/bwcc in Clinical Affiliation With South Shore Hospital
South Weymouth, Massachusetts, United States
- Lifespan
Providence, Rhode Island, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Vanderbilt University Medical Center
Nashville, Tennessee, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 May 2016
- Primary completion
- 28 Feb 2022
- Completion
- 30 Apr 2031
- Last update posted
- 23 Jun 2026
- Registered enrollment
- 195
- Registry id
- NCT02764541
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.